



**PRESS RELEASE
FOR IMMEDIATE DISTRIBUTION
Jan 24, 2012**

ARCH BIOPARTNERS APPOINTS CLAUDE ALLARY AS SPECIAL ADVISOR

Toronto, ON – Jan 24, 2012 - Arch Biopartners Inc (“Arch” or the “Company”)(CNSX-ACH and OTC: FOIFF) announced today Claude Allary has been appointed Special Advisor to the Company. In this capacity, Mr. Allary will provide expertise in evaluating commercial opportunities for the Company’s drug development platforms and other emerging technologies.

Mr. Allary is currently a managing partner of Bionest, a pharmaceutical consulting firm with offices in Paris and New York that he co-founded in 2003. Prior to Bionest, Mr Allary accumulated over 20 years of experience within the pharmaceutical industry, successively with Rhône-Poulenc Santé (now Sanofi), Parke-Davis (now Pfizer) and Glaxo. He also spent 7 years with Arthur D. Little in London, Brussels and Paris, followed by 4 years with ISO Health Care Group (now Monitor) in Paris

“Mr Allary brings vast knowledge and experience in the commercial assessment, development and market positioning of new drug candidates and we feel extremely fortunate to have Mr Allary working with our team” said Mr. Jerry McElroy, Chairman of Arch.

About Arch Biopartners

Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies.

For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.

The Company’s website address is: www.archbiopartners.com .

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.

The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.

For more information, please contact:

Richard Muruve

CEO, Arch Biopartners Inc.

(647) 428 7031

info@archbiopartners.com